Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Proof of concept
- 20 Jul 2017 Results published in the Journal of Urology
- 02 May 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.